Skip to main content

Table 4 Multivariate analysis for biochemical breakthrough after lamivudine cessation in all 138 patients

From: Clinical course of chronic hepatitis B patients who were off-treated after lamivudine treatment: analysis of 138 consecutive patients

Variable

Univariate analysis

Multivariate analysis*

 

HR

95% C.I

P-value

HR

95% C.I

P-value

Age at cessation (≥40 years)

1.001

0.611-1.639

0.998

-

-

-

Sex (female)

0.396

0.225-0.696

0.001

0.372

0.209-0.663

0.001

Initial HBeAg-positive

2.469

1.288-4.735

0.007

2.435

1.249-4.750

0.009

HBV DNA (Log10copies/mL) +

1.075

0.866-1.335

0.512

-

-

-

Total treatment duration (months)

1.000

0.987-1.013

0.957

-

-

-

HBV DNA levels (copies/mL) ‡

<50 (control)

   50-104

2.515

1.402-4.514

0.002

1.847

1.018-3.350

0.043

   ≥104

5.656

2.964-10.793

<0.001

5.249

2.608-9.553

<0.001

  1. C.I, confidence interval; HBV, hepatitis B virus; HR, hazard ratio.
  2. +Serum HBV DNA level at initiation of lamivudine treatment.
  3. ‡Serum HBV DNA level at cessation of lamivudine treatment.
  4. * Cox Proportional Hazards model with a backward elimination method.
Back to article page

Virology Journal

ISSN: 1743-422X